Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730010 · ClinicalTrials.gov registry record
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 289
- Enrollment target
NCT05730010: Completed study, sponsored by Indiana University.
NCT05730010 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 289 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05730010 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 289 participants
- Enrollment target
Study Summary
This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
Primary Outcome
Ratings- based analysis will be used to examine whether knowledge of ctDNA negativity increases patient acceptability (and if so, by how much) of no therapy in the adjuvant setting, compared to standard of care capecitabine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2023-04-16 |
| Est. Completion | 2023-06-26 |
What the finished NCT05730010 record still lists
NCT05730010 is an observational study that tracks outcomes without assigning an intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05730010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05730010 about?
NCT05730010 is a clinical study titled "Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis". This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
What is the current status of trial NCT05730010?
This trial is currently completed. The enrollment target is 289 participants. The study started on 2023-04-16. Estimated completion is 2023-06-26.
Who is sponsoring clinical trial NCT05730010?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI